We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Pathway That Enables Movement of Metastatic Cancer Cells Identified

By LabMedica International staff writers
Posted on 16 Oct 2011
Cancer researchers have identified a molecular pathway that seems to be responsible for the ability of metastatic tumor cells to change shape and travel.

Investigators at the University of Michigan (Ann Arbor, USA) worked with breast cancer cells growing in culture. More...
Previous studies had shown that aggressively metastatic breast cancer cells usually overexpressed the RhoC (aplysia ras-related homolog 9) gene. In this study, they searched for the molecular trigger for RhoC expression.

They reported in the August 23, 2011, online edition of the journal Cancer Research that the protein p38gamma was directly linked to RhoC activation. P38gamma is one member of the p38 MAPK (p38 mitogen-activated protein kinase) class of mitogen-activated protein kinases. These enzymes are responsive to stress stimuli, such as cytokines, ultraviolet irradiation, heat shock, and osmotic shock, and are involved in cell differentiation and apoptosis.

Results from experiments with breast cancer cell cultures revealed that inactivation of p38gamma caused cells to flatten out and shift from fast motion to ineffective movement. Clinical relevance indicated that elevated expression of p38gamma was associated with lower overall survival of breast cancer patients. The critical role of p38gamma was further emphasized by data generated from a mathematical model that described how various molecules contributed to cell movement.

“Normal motion is commonly seen in aggressive cancers, which is why it is very important to understand what the key switches are for this motion,” said senior author Dr. Sofia Merajver, professor of internal medicine at the University of Michigan. “Cell movement is very difficult to observe, which is why mathematical modeling in oncology is valuable. This gives us a more complete understanding of how aggressive breast cancer cells move and the influence of p38gamma in particular on modifying this motion.”

“We do have targeted therapies in the clinic, but the total burden of disease that they ameliorate is still relatively minimal. The reasons may not necessarily be that they are not good drugs, but simply that we do not understand how they work, because we do not understand the biology in sufficient detail. That’s why studies like this are so important in advancing drug development,” said Dr. Merajver.

Related Links:
University of Michigan



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.